Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

[1]  E. Oermann,et al.  Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer , 2013, Radiation Oncology.

[2]  E. Oermann,et al.  A Dosimetric and Clinical Evaluation of Monotherapy With Hypofractionated Stereotactic Body Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer , 2012 .

[3]  A. D'Amico,et al.  Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. , 2012, The Journal of urology.

[4]  I. Kaplan,et al.  Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinoma , 2012, Cancer.

[5]  C. Kirisits,et al.  Late gastrointestinal and urogenital side-effects after radiotherapy--incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  H. Sandler,et al.  Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy , 2012, Radiation Oncology.

[7]  A. Katz.  Stereotactic body radiotherapy for prostate cancer: ready for prime time? , 2012, Journal of Radiation Oncology.

[8]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[9]  Joshua D. Lawson,et al.  A survey of stereotactic body radiotherapy use in the United States , 2011, Cancer.

[10]  C. King,et al.  Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes , 2011, Radiation oncology.

[11]  John T. Wei,et al.  Comparison of validated instruments measuring sexual function in men. , 2010, Urology.

[12]  M. Santoro,et al.  Stereotactic body radiotherapy for organ-confined prostate cancer , 2010, BMC urology.

[13]  Ping Xia,et al.  Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[14]  C. King,et al.  Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. , 2009, International journal of radiation oncology, biology, physics.

[15]  B. Leiby,et al.  Time of decline in sexual function after external beam radiotherapy for prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[16]  V. Seshan,et al.  Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. , 2009, International journal of radiation oncology, biology, physics.

[17]  W. J. Morris,et al.  Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. , 2009, International journal of radiation oncology, biology, physics.

[18]  Jay L. Friedland,et al.  Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer , 2009, Technology in cancer research & treatment.

[19]  J. Gore,et al.  Erectile aid use by men treated for localized prostate cancer. , 2009, The Journal of urology.

[20]  N. Lumen,et al.  Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  N. Mohideen,et al.  Predictors of response to sildenafil citrate following radiation therapy for prostate cancer. , 2009, The journal of sexual medicine.

[22]  Avid,et al.  INTRAFRACTIONAL MOTION OF THE PROSTATE DURING HYPOFRACTIONATED RADIOTHERAPY , 2009 .

[23]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[24]  G. Pond,et al.  Long-term urinary sequelae following 125iodine prostate brachytherapy. , 2008, The Journal of urology.

[25]  W. Lee,et al.  Hypofractionation for prostate cancer: a critical review. , 2008, Seminars in radiation oncology.

[26]  G. Lockwood,et al.  PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.

[27]  J. Fowler,et al.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. , 2007, International journal of radiation oncology, biology, physics.

[28]  P. Albert,et al.  An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma , 2007, Prostate Cancer and Prostatic Diseases.

[29]  D. Kuban,et al.  Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone , 2006, Cancer.

[30]  John T. Wei,et al.  Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. , 2006, Urology.

[31]  J. Ciezki,et al.  PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. , 2006, International journal of radiation oncology, biology, physics.

[32]  J. Stanford,et al.  Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. , 2005, The Journal of urology.

[33]  Wayne M Butler,et al.  Erectile function after prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[34]  J. Fowler,et al.  The radiobiology of prostate cancer including new aspects of fractionated radiotherapy , 2005, Acta oncologica.

[35]  Caitlin Gillan,et al.  Posttreatment Complications of Early‐Stage Prostate Cancer Patients: Brachytherapy Versus Three‐Dimensional Conformal Radiation Therapy , 2005, Cancer journal.

[36]  R. Stock,et al.  Urinary symptom flare following I-125 prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[37]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[38]  J. Cappelleri,et al.  The International Index of Erectile Function (IIEF): a state-of-the-science review , 2002, International Journal of Impotence Research.

[39]  W. Butler,et al.  Temporal resolution of urinary morbidity following prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[40]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[41]  W H Rogers,et al.  Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. , 1995, Medical care.

[42]  J. Ware,et al.  What information do consumers want and how will they use it? , 1995, Medical care.

[43]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.